Company profile
UK company 04948632, incorporated on 30 October 2003.
CellCentric The p300/CBP inhibitor company
Cellcentric Limited is a UK company with status active founded in 2003 based in East of England.
Company number 04948632
Reference milestones and recent Companies House filing stream events.
RESOLUTIONS | Transaction WUY3REdQVVBhZGlxemtjeA | Paper/PDF filed
Published 07 Aug 2026 23:07
MA | Transaction MzUzNjAzMTY1MWFkaXF6a2N4 | Paper/PDF filed
Published 07 Aug 2026 23:06
CS01 | Transaction MzUyNzgwOTMzOWFkaXF6a2N4
Published 22 Jun 2026 17:24
RP01AP01 | Transaction MzUyNDcwMzc3NmFkaXF6a2N4
Published 15 Aug 2026 05:05
Company registered at Companies House
Engaged in medical applications resulting from advances in epigenetic mechanisms.
Close links with Takeda for investigations on targets of cancers such as prostate.
1 Jan 2017 to 31 Dec 2017
1 in 4 cancer deaths in men and women are a result of lung cancer. Despite significant advances in recent years, both in terms of early detection and novel therapies, there remains a significant unmet need for cost-effective drugs that offer long term benefits. CellCentric has developed a novel, highly potent potential drug for the aggressive form of pros...
1 Jun 2013 to 30 Sep 2015
Prostate cancer is the second leading cause of mortality among men. Initial treatments focus on reducing the levels of circulating male hormones in the body which the cancer requires for growth. Overtime however, in 10-20% of cases, the cancer cells circumvent this treatment and develop into ‘castration-resistant’ prostate cancer (CRPC). This is the letha...
1 Dec 2009 to 31 Mar 2013
The aim is to develop a process which can distinguish good from bad induced pluripotent stem cells (iPS cells) in terms of their differentiation capacity. Batches of iPS cells derived from multiple patient tissue samples will be analysed and grouped in terms of their ability to differentiate into the three cell lineages (endoderm, mesoderm and ectoderm). ...
1 Apr 2006 to 30 Sep 2009
Awaiting Public Summary
